文献类型：期刊文献

英文题名：The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis

作者：Zhang, Lu[1,2];Liu, Tianlong[3];Li, Xiaolin[3];Chen, Sirui[1,2];Wang, Shengguang[2,3];Ma, Huiping[2,3];Liu, Minna[1]

第一作者：张立;张丽;张雷;张乐;张磊;张玲;Zhang, Lu

通信作者：Liu, MN[1]

机构：[1]940th Hosp Joint Logist Support Forces PLA, Fundamental Med Sci Res Labs, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Gansu, Peoples R China;[3]940th Hosp Joint Logist Support Forces PLA, Dept Pharm, Lanzhou, Gansu, Peoples R China

第一机构：940th Hosp Joint Logist Support Forces PLA, Fundamental Med Sci Res Labs, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), 940th Hosp Joint Logist Support Forces PLA, Fundamental Med Sci Res Labs, Lanzhou, Gansu, Peoples R China.

年份：2026

卷号：21

外文期刊名：INTERNATIONAL JOURNAL OF NANOMEDICINE

收录：;Scopus(收录号：2-s2.0-105045672133);WOS:【SCI-EXPANDED(收录号:WOS:001831140000001)】；

基金：This research was funded by National Natural Science Foundation of China (82204746), Natural Science Foundation of Gansu Province (25JRRA810), Natural Science Foundation of Lanzhou (2024-9-132, 2024-9-135), Special Cultivation Project of the 940th Hospital (2021yxky026) and Major Science and Technology Projects of Gansu Province (24ZDFA008) .

语种：英文

外文关键词：chronic kidney disease; renal fibrosis; traditional Chinese medicine; nano-preparations; renal targeting

摘要：Chronic kidney disease (CKD) is a global public health threat, and renal fibrosis represents the common pathological pathway toward end-stage disease. Current clinical treatments are limited by single-target mechanisms and their inability to reverse established fibrosis. Traditional Chinese medicine (TCM) offers multi-target advantages but encounters challenges including low bioavailability and lack of targeting. Nanodelivery systems overcome these limitations by enabling precise renal targeting and enhanced efficacy. This review provides a comprehensive and systematic overview of the mechanisms and applications of TCM nanoformulations for anti-renal fibrosis, with an emphasis on bridging nanocarrier material properties to clinical translation potential. To achieve this, we summarize the pathogenesis of renal fibrosis, elucidate the principles of renal-targeted nano-delivery (glomerular filtration, tubular reabsorption, and secretion), categorize five classes of nanocarriers with their physicochemical properties and in vivo fate, review the anti-fibrotic mechanisms and nanodelivery strategies of four major TCM active components (flavonoids, anthraquinones, phenolic compounds, and glycosides), and present preclinical evidence in CKD and acute kidney injury (AKI) models. In conclusion, TCM nanoformulations represent a promising strategy for renal fibrosis treatment by integrating multi-component synergy with precise renal targeting. However, significant hurdles remain, including batch-to-batch consistency, long-term safety evaluation, and regulatory pathway establishment. Addressing these challenges is essential for successful clinical translation.